BenevolentAI

At a glance

Pricing

Enterprise / partnership.

HIPAA

Not disclosed

SOC 2

Not disclosed

EHRs

—

Founded

—

HQ

UK

Bottom line

Knowledge-graph AI for target ID and drug repurposing.

Free tier available.

Overview

Pricing

What it costs

Free tier only; no paid plans publicly disclosed.

Source: vendor pricing page. Verified May 23, 2026.

Peer-reviewed coverage

What the literature says

5 peer-reviewed studies indexed on PubMed evaluate BenevolentAI in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.

Artificial intelligence revolution in drug discovery: A paradigm shift in pharmaceutical innovation.

Jarallah SJ, Almughem FA, Alhumaid NK, et al.· Int J Pharm· 2025

Integrating artificial intelligence (AI) into drug discovery has revolutionized pharmaceutical innovation, addressing the challenges of traditional methods that are costly, time-consuming, and suffer from high failure rates. By utilizing machine learning (ML), deep learning (DL), and natural language processing (NLP), AI enhances various stages of drug development, including target identification, lead optimization, de novo drug design, and drug repurposing. AI tools, such as AlphaFold for protein structure prediction and AtomNet for structure-based drug design, have significantly accelerated…

Artificial Intelligence in Small-Molecule Drug Discovery: A Critical Review of Methods, Applications, and Real-World Outcomes.

Niazi SK· Pharmaceuticals (Basel)· 2025

Artificial intelligence (AI) is emerging as a valuable complementary tool in small-molecule drug discovery, augmenting traditional methodologies rather than replacing them. This review examines the evolution of AI from early rule-based systems to advanced deep learning, generative models, diffusion models, and autonomous agentic AI systems, highlighting their applications in target identification, hit discovery, lead optimization, and safety prediction. We present both successes and failures to provide a balanced perspective. Notable achievements include baricitinib (BenevolentAI/Eli Lilly, a…

Exploring pre-diagnosis hospital contacts in women with endometriosis using ICD-10: a Danish case-control study.

Melgaard A, Vestergaard CH, Kesmodel US, et al.· Hum Reprod· 2025

How does pre-diagnosis use of hospital care differentiate between women later diagnosed with endometriosis and age-matched controls without a diagnosis? Women with hospital-diagnosed endometriosis had more frequent hospital contacts in the 10 years leading up to the diagnosis compared to women without a diagnosis of endometriosis, and the contacts were related to registered diagnoses in nearly all of the included ICD-10 chapters for the entire period. Only a few studies have investigated the utilization of health care among women with endometriosis in the time before diagnosis, but cur…

Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer.

Puleo N, Ram H, Dziubinski ML, et al.· Mol Cancer Ther· 2025

Up to 90% of patients with high-grade serous ovarian cancer (HGSC) will develop resistance to platinum-based chemotherapy, posing substantial therapeutic challenges due to a lack of universally druggable targets. Leveraging BenevolentAI's artificial intelligence (AI)-driven approach to target discovery, we screened potential AI-predicted therapeutic targets mapped to unapproved tool compounds in patient-derived 3D models. This identified TNIK, which is modulated by NCB-0846, as a novel target for platinum-resistant HGSC. Targeting by this compound demonstrated efficacy across both in vitro an…

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.

Richardson PJ, Smith DP, de Giorgio A, et al.· Transl Neurodegener· 2023

Amyotrophic lateral sclerosis (ALS) is a poorly treated multifactorial neurodegenerative disease associated with multiple cell types and subcellular organelles. As with other multifactorial diseases, it is likely that drugs will need to target multiple disease processes and cell types to be effective. We review here the role of Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) signalling in ALS, confirm the association of this signalling with fundamental ALS disease processes using the BenevolentAI Knowledge Graph, and demonstrate that inhibitors of this pat…

See all on PubMed